ArriVent BioPharma, Inc.'s total assets for Q3 2025 were $326.56M, an increase of 21.17% from the previous quarter. AVBP total liabilities were $21.56M for the fiscal quarter, a 9.79% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.